9I
9IP1.F Rocket Pharmaceuticals Inc
- Market cap
- EUR 244M
- P/E
- -
- P/B
- 0.72x
- ROE
- 41.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 9IP1.F undervalued?
Graham numberThe Graham number of Rocket Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Rocket Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Rocket Pharmaceuticals Inc yet.
Rocket Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakop…
Full company profileRocket Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Rocket Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -41.9M | -26.7M | -71.2M | -76.2M | -134M | -166M | -224M | -260M | -273M | -229M | -191M |
| EBITDA | - | -25.7M | -68.1M | -70.9M | -132M | -163M | -214M | -237M | -247M | -210M | 179M |
| Net Income | -42.9M | -29.5M | -74.5M | -77.3M | -140M | -169M | -222M | -246M | -259M | -223M | 151M |
| EPS | - | -4.33 | -1.65 | -1.41 | -2.29 | -2.62 | -2.80 | -2.72 | -2.43 | -2.06 | 1.38 |
| Balance Sheet | |||||||||||
| Total Assets | 130M | 102M | 251M | 372M | 591M | 497M | 552M | 566M | 528M | 330M | 423M |
| Total Liabilities | 56.5M | 54.0M | 57.3M | 64.8M | 87.3M | 42.3M | 62.1M | 73.8M | 64.5M | 53.2M | 54.3M |
| Shareholders' Equity | 73.2M | 47.8M | 194M | 307M | 504M | 455M | 490M | 493M | 463M | 277M | 369M |
| Cash & Short-term Investments | 29.8M | 78.7M | 111M | 185M | 297M | 233M | 141M | 55.9M | 164M | 77.6M | 225M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -5.50M | -16.0M | -53.8M | -64.7M | -74.6M | -121M | -178M | -195M | -210M | -190M | -170M |
| Capital Expenditure | 487K | 760K | 1.45M | 23.3M | 20.6M | 7.62M | 8.36M | 16.5M | 5.86M | 440K | 202K |
| Free Cash Flow | - | -26.2M | -55.2M | -87.9M | -104M | -129M | -187M | -211M | -216M | -190M | -170M |
| Ratios | |||||||||||
| ROE | -58.6% | -61.8% | -38.4% | -25.1% | -27.7% | -37.2% | -45.3% | -49.9% | -55.9% | -80.5% | 41.0% |
| ROA | -33.1% | -29.0% | -29.7% | -20.8% | -23.6% | -34.0% | -40.2% | -43.4% | -49.0% | -67.5% | 35.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Rocket Pharmaceuticals Inc dividends
Rocket Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:4 on Jan 5, 2018.
Who owns Rocket Pharmaceuticals Inc
- Insiders 3.19%
- Institutions 88.75%
- Public & others 8.06%
- Shares outstanding 110M
- Free float 87.7M
Rocket Pharmaceuticals Inc company profile
- Company name
- Rocket Pharmaceuticals Inc
- Ticker
- 9IP1.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 202
- Fiscal year end
- December
- Address
- 9 Cedarbrook Drive, Cranbury, NJ, United States, 08512
- Phone
- 609 659 8001
- Website
- rocketpharma.com
About Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops ex vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
Rocket Pharmaceuticals Inc management
9- Dr. Gaurav D. Shah M.D.CEO & Director · born 1975
- Mr. Martin Louis Wilson J.D.Gen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer · born 1976
- Mr. Christopher StevensChief Operating Officer · born 1980
- Mr. Joseph ManhedePrincipal Accounting Officer · born 1978
- Dr. Jonathan Schwartz M.D.Chief Science & Gene Therapy Officer · born 1964
- Ms. Meg E. Dodge J.D., L.L.M.Senior Vice President & Head of External Affairs
- Ms. Sarbani Chaudhuri M.B.A.Chief Commercial Officer · born 1975
- Dr. Syed Ali-Aamir Rizvi M.D.Chief Medical Officer · born 1967
- Kevin GiordanoDirector of Corporate Communications